Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Equity Average (2016 - 2025)

Historic Equity Average for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to $5.0 million.

  • Silo Pharma's Equity Average fell 2208.88% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 2208.88%. This contributed to the annual value of $5.6 million for FY2024, which is 3212.63% down from last year.
  • Latest data reveals that Silo Pharma reported Equity Average of $5.0 million as of Q3 2025, which was down 2208.88% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Silo Pharma's Equity Average peaked at $11.1 million during Q4 2022, and registered a low of $2.8 million during Q1 2021.
  • Over the past 5 years, Silo Pharma's median Equity Average value was $6.8 million (recorded in 2023), while the average stood at $7.0 million.
  • Per our database at Business Quant, Silo Pharma's Equity Average soared by 203695.23% in 2021 and then crashed by 4203.1% in 2024.
  • Over the past 5 years, Silo Pharma's Equity Average (Quarter) stood at $9.6 million in 2021, then grew by 15.52% to $11.1 million in 2022, then plummeted by 38.39% to $6.8 million in 2023, then dropped by 13.58% to $5.9 million in 2024, then dropped by 16.0% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $4.5 million for Q2 2025, and $4.5 million during Q1 2025.